EyePoint (EYPT) Cash from Operations Growth (3y) (2013 - 2026)
EyePoint (EYPT) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 34.32% |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | -68.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.51% |
| Dec 31, 2025 | -72.88% |
| Sep 30, 2025 | -65.32% |
| Jun 30, 2025 | -48.47% |
| Mar 31, 2025 | -38.12% |
| Dec 31, 2024 | -29.08% |
| Sep 30, 2024 | -71.13% |
| Jun 30, 2024 | -24.16% |
| Mar 31, 2024 | -27.33% |
| Dec 31, 2023 | -80.90% |
| Sep 30, 2023 | -148.71% |
| Jun 30, 2023 | 135.95% |
| Mar 31, 2023 | -0.99% |
| Dec 31, 2022 | -3.10% |
| Sep 30, 2022 | 3.84% |
| Jun 30, 2022 | -3.78% |
| Mar 31, 2022 | -14.77% |
| Dec 31, 2021 | 9.63% |
| Sep 30, 2021 | 29.96% |
| Jun 30, 2021 | 1.11% |